Developer docs
API playgroundTry for free, no card

Search company profiles

Remap Consulting

Full company profile

uuid000exg2

Namestring
Remap Consulting
Legal namestring
Remap Consulting GmbH
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Remap Consulting is a privately held, founder-owned pharmaceutical pricing and market access consultancy founded in January 2014 by Paul Craddy, who previously led diabetes pricing and market access for Takeda's EUCAN region. Headquartered in Zug, Switzerland (Remap Consulting GmbH) with a UK delivery hub in Alderley Park, Cheshire (Remap Consulting UK Ltd), the firm provides specialist advisory services to global pharmaceutical and biotechnology companies, including Amgen, Inventiva, Ipsen, Nestlé Health Science, and Krystal Biotechnology. The firm reports having worked with 161 pharma and biotech companies, including 11 of the top 20 global pharmaceutical companies, supported pricing and access strategies across 57 countries, and participated in over 60 pricing and reimbursement submissions across 25 countries.

The company's service portfolio is organized around three lines: Launch Implementation (pricing and reimbursement launch strategy, Joint Clinical Assessment support, Joint Scientific Consultation, HTA/payer early dialogue, payer value communication), Pricing (payer insights, pricing strategy, BD commercial assessments, tactical pricing including international reference price analysis), and Training (on-demand eLearning, interactive workshops, and visual training aids). The team of roughly 35-40 professionals carries extensive academic credentials (multiple PhDs from Oxford, Manchester, UCL, Imperial, Durham) and prior tenures at NICE, Pfizer, J&J, AbbVie, Takeda, GSK, Ferring, IQVIA, EY-Parthenon, Avalere Health, and PRMA Consulting. The firm has productized one AI-powered asset, the Remap JCA Advisor, a free knowledge retrieval tool that interprets EU HTA Regulation and Joint Clinical Assessment processes.

Revenue is generated on a professional services basis through bespoke consulting engagements and training delivery. The firm does not disclose pricing; engagements are project-based with bespoke scoping adapted to client needs. Go-to-market is predominantly direct enterprise sales supported by content-driven marketing, including a publication cadence of articles and webinars, active participation in industry conferences (ISPOR, HTAi, World Orphan Drug Congress), and strategic alliances with Medvance, EUCOPE, ISPOR, the Swiss Biotech Association, BHBIA, and Regulanet. Training is delivered with a stated 95% positive feedback rate. The firm holds a 2024 EcoVadis Silver Sustainability Rating and remains independently owned with no disclosed external institutional investment, no parent company, and no subsidiaries.

Short descriptiontext

Remap Consulting is a specialist pharmaceutical pricing and market access consultancy, founded in 2014 and headquartered in Zug, Switzerland, serving global pharma and biotech companies with launch strategy, HTA submissions, payer value communication, and training across 57 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersZug, Switzerland
HQ citystring
Zug
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical pricing, market access consulting, health technology assessment, value communication, HTA submissions
Industry2 codes
PRIMARYBPAHACAG
Customer, Marketing & Sales Consulting
SECONDARYBPAHACAB
Operations & Process Improvement Consulting
NAICS code1 code
  • Management Consulting Services54161
SIC code1 code
  • Services-Management Consulting Services8742
Product category
Pharmaceutical Market Access Consulting
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Consulting Services
TypeProfessional Services
Description

Professional consulting engagements providing pricing and market access strategy services to pharmaceutical and biotech companies. Engagements include launch strategy, HTA submissions, payer value communication, and training services. Revenue is generated through project-based consulting fees for strategic advisory work.

remapconsulting.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Remap Consulting is a specialist market access and pharmaceutical pricing consultancy that helps drug developers launch products, optimize pricing, and navigate health technology assessment (HTA) and reimbursement processes across global markets. The firm delivers bespoke consulting across launch strategy, payer value communication, pricing strategy, business development commercial assessments, and market access training for pharmaceutical and biotechnology clients. Services are supported by a free AI-powered tool, the Remap JCA Advisor, for navigating EU HTA regulation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 95% positive feedback from training course participants
+3 more records
Product overview1 text field

Remap Consulting is a pricing and market access consultancy offering a comprehensive suite of services organized into three main areas: Launch (covering pricing/reimbursement strategy, Joint Clinical Assessment, Joint Scientific Consultation, HTA/payer early dialogue, and payer value communication), Pricing (encompassing payer insights, pricing strategy, BD commercial assessments, and tactical pricing), and Training (including on-demand eLearning, interactive workshops, and visual training aids). The firm also offers an AI-powered tool called the Remap JCA Advisor for navigating EU HTA processes. Services are delivered by a team of market access experts and are designed to help pharmaceutical and biotech companies optimize pricing and achieve successful market access.

Product and service8 records
1Launch Implementation
CategoryPharmaceutical Launch Consulting
Description

Develops and implements pricing and market access launch strategies for pharmaceutical products, including support for global, regional, and local teams, HTA/pricing/reimbursement submissions, and payer scientific advice integration.

2Pricing & Reimbursement Launch Strategy
CategoryPricing Strategy Consulting
Description

Comprehensive strategy covering market access opportunity assessment, payer strategy development, HTA landscape assessments, indication sequencing optimization, clinical trial input optimization, and HTA/reimbursement submissions including NICE and EU Joint Clinical Assessments.

3Joint Clinical Assessment
CategoryHTA Consulting
Description

Expertise in EU HTA Joint Clinical Assessment process, including JCA dossier writing, PICO development, stakeholder liaison, and strategic guidance for navigating the pan-European clinical assessment process for drugs and medical devices.

4Joint Scientific Consultation
CategoryHTA Consulting
Description

Strategic guidance for engaging with HTA bodies under EU HTA Regulation, including strategic preparation for JSC submissions, stakeholder coordination, evidence generation advice, and post-JSC action planning.

5HTA & Payer Early Dialogue
CategoryMarket Access Consulting
Description

Formal and informal payer insights for clinical trial designs including Joint Scientific Consultations, NICE scientific advice, Office of Market Access engagement, payer scientific advice, early access opportunities, advisory boards, and payer insights research.

6Payer Value Communication Strategy
CategoryValue Communication Consulting
Description

Development of payer value communication materials including Global Value Dossiers, payer value driver identification, value message development, value story testing, objection handling, and formulary access tools.

7Payer Insights
CategoryMarket Research Consulting
Description

Utilizes an extensive global payer network to obtain payer research insights addressing pharma pricing and market access strategy needs, including pharmaceutical pricing research, Target Product Profile testing, value message testing, payer advisory boards, and mock payer negotiations.

8Pricing Strategy
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

As the UK partner for Medvance, Remap Consulting addresses the market access challenges of pharmaceutical companies in Great Britain. Medvance is a European-wide healthcare consultancy group.

2EUCOPE
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The European Confederations of Pharmaceutical Entrepreneurs. Remap is an active member, presenter and regular contributor to EUCOPE, participating in industry discussions on pharmaceutical policy and market access.

remapconsulting.com
3Regulanet
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Remap is a member of regulanet®, providing pricing and market access expert insights to support members of regulanet® network.

remapconsulting.com
4Swiss Biotech Association
Strategic tierMinorTypeOthers
Description

Affiliation with the Swiss Biotech Association which represents the interests of the Swiss Biotech industry.

remapconsulting.com
Strategic tierMinorTypeOthers
Description

The industry association for thought leadership, professional development and ethical standards for deriving insights within UK healthcare.

Strategic tierCoreTypeOthers
Description

The leading professional society for health economics and outcomes research (HEOR) globally. Remap participates in ISPOR events and conferences as presenters and attendees.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based specialist pharma consultancy providing HTA submissions, market access, HEOR and value communications — directly comparable in service mix and target customer base to Remap.

TypeDirect peer
Description

Boutique pharma strategy and market access consultancy with strong HTA/payer expertise — comparable in offering, customer type (global pharma), and boutique positioning.

TypeDirect peer
Description

Specialist pricing, market access and HEOR consultancy serving pharma and biotech — same core offering, same client set, and the firm where several Remap senior team members (e.g. Christina Baker, Nicole Lodowski) built their careers.

TypeDirect peer
Description

UK-based specialist market access consultancy focused on pricing, HTA submissions and payer engagement for pharma/biotech — directly comparable niche positioning to Remap.

TypeBroad incumbent
Description

Large HEOR, market access and HTA consulting arm within PPD, providing value evidence, pricing and payer communications — same service envelope as Remap but inside a much larger CRO platform.

TypeBroad incumbent
Description

Global life-sciences technology and consulting platform with market access and pricing practice — provides overlapping capabilities but as part of a much wider portfolio (Andrea Latour's previous employer).

TypeBroad incumbent
Description

Global consulting firm with dedicated Life Sciences practice covering pricing, market access and commercial strategy for pharma — broader portfolio but directly comparable pricing/market access service line.

TypeBroad incumbent
Description

Global health communications and consulting group including FH/Real Chemistry providing market access, HEOR and value communications — overlaps with Remap's payer value communication work as part of a broader agency offering.

9LCP Health Analytics
TypeDirect peer
Description

UK health economics and market access analytics consultancy — a specialist with comparable HTA/payer analytics focus (recent employer of Remap consultant Grace Miller).

10Syreon Research Institute
TypeRegional player
Description

European HEOR and market access research institute covering HTA submissions, health economics and pricing research — comparable service offering with primary European focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Remap Consulting

Pharmaceutical Market Access Consultingremapconsulting.com

Remap Consulting is a specialist pharmaceutical pricing and market access consultancy, founded in 2014 and headquartered in Zug, Switzerland, serving global pharma and biotech companies with launch strategy, HTA submissions, payer value communication, and training across 57 countries.

What Remap Consulting does

Remap Consulting is a privately held, founder-owned pharmaceutical pricing and market access consultancy founded in January 2014 by Paul Craddy, who previously led diabetes pricing and market access for Takeda's EUCAN region. Headquartered in Zug, Switzerland (Remap Consulting GmbH) with a UK delivery hub in Alderley Park, Cheshire (Remap Consulting UK Ltd), the firm provides specialist advisory services to global pharmaceutical and biotechnology companies, including Amgen, Inventiva, Ipsen, Nestlé Health Science, and Krystal Biotechnology. The firm reports having worked with 161 pharma and biotech companies, including 11 of the top 20 global pharmaceutical companies, supported pricing and access strategies across 57 countries, and participated in over 60 pricing and reimbursement submissions across 25 countries.

The company's service portfolio is organized around three lines: Launch Implementation (pricing and reimbursement launch strategy, Joint Clinical Assessment support, Joint Scientific Consultation, HTA/payer early dialogue, payer value communication), Pricing (payer insights, pricing strategy, BD commercial assessments, tactical pricing including international reference price analysis), and Training (on-demand eLearning, interactive workshops, and visual training aids). The team of roughly 35-40 professionals carries extensive academic credentials (multiple PhDs from Oxford, Manchester, UCL, Imperial, Durham) and prior tenures at NICE, Pfizer, J&J, AbbVie, Takeda, GSK, Ferring, IQVIA, EY-Parthenon, Avalere Health, and PRMA Consulting. The firm has productized one AI-powered asset, the Remap JCA Advisor, a free knowledge retrieval tool that interprets EU HTA Regulation and Joint Clinical Assessment processes.

Revenue is generated on a professional services basis through bespoke consulting engagements and training delivery. The firm does not disclose pricing; engagements are project-based with bespoke scoping adapted to client needs. Go-to-market is predominantly direct enterprise sales supported by content-driven marketing, including a publication cadence of articles and webinars, active participation in industry conferences (ISPOR, HTAi, World Orphan Drug Congress), and strategic alliances with Medvance, EUCOPE, ISPOR, the Swiss Biotech Association, BHBIA, and Regulanet. Training is delivered with a stated 95% positive feedback rate. The firm holds a 2024 EcoVadis Silver Sustainability Rating and remains independently owned with no disclosed external institutional investment, no parent company, and no subsidiaries.

Remap Consulting firmographics

Firmographics
Name
Remap Consulting
Legal name
Remap Consulting GmbH
Website
https://remapconsulting.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Remap Consulting is a specialist pharmaceutical pricing and market access consultancy, founded in 2014 and headquartered in Zug, Switzerland, serving global pharma and biotech companies with launch strategy, HTA submissions, payer value communication, and training across 57 countries.
Ownership category
akta.pro rank

Remap Consulting industry classification

Industry
Product category
Pharmaceutical Market Access Consulting
NAICS
Management Consulting Services (54161)
SIC
Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYBPAHACAG
Customer, Marketing & Sales Consulting
SECONDARYBPAHACAB
Operations & Process Improvement Consulting

Keywords

  • Pharmaceutical pricing
  • Market access consulting
  • Health technology assessment
  • Value communication
  • HTA submissions

Where Remap Consulting is headquartered

Location

Headquarters

HQ city
Zug
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Remap Consulting business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Consulting Services: Professional consulting engagements providing pricing and market access strategy services to pharmaceutical and biotech companies. Engagements include launch strategy, HTA submissions, payer value communication, and training services. Revenue is generated through project-based consulting fees for strategic advisory work.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Remap Consulting product offering

Product offering

Core offering

Remap Consulting is a specialist market access and pharmaceutical pricing consultancy that helps drug developers launch products, optimize pricing, and navigate health technology assessment (HTA) and reimbursement processes across global markets. The firm delivers bespoke consulting across launch strategy, payer value communication, pricing strategy, business development commercial assessments, and market access training for pharmaceutical and biotechnology clients. Services are supported by a free AI-powered tool, the Remap JCA Advisor, for navigating EU HTA regulation.

Product overview

Remap Consulting is a pricing and market access consultancy offering a comprehensive suite of services organized into three main areas: Launch (covering pricing/reimbursement strategy, Joint Clinical Assessment, Joint Scientific Consultation, HTA/payer early dialogue, and payer value communication), Pricing (encompassing payer insights, pricing strategy, BD commercial assessments, and tactical pricing), and Training (including on-demand eLearning, interactive workshops, and visual training aids). The firm also offers an AI-powered tool called the Remap JCA Advisor for navigating EU HTA processes. Services are delivered by a team of market access experts and are designed to help pharmaceutical and biotech companies optimize pricing and achieve successful market access.

Differentiator

Problem solved

Functional benefit

Products and services

  • Launch Implementation Develops and implements pricing and market access launch strategies for pharmaceutical products, including support for global, regional, and local teams, HTA/pricing/reimbursement submissions, and payer scientific advice integration.
  • Pricing & Reimbursement Launch Strategy Comprehensive strategy covering market access opportunity assessment, payer strategy development, HTA landscape assessments, indication sequencing optimization, clinical trial input optimization, and HTA/reimbursement submissions including NICE and EU Joint Clinical Assessments.
  • Joint Clinical Assessment Expertise in EU HTA Joint Clinical Assessment process, including JCA dossier writing, PICO development, stakeholder liaison, and strategic guidance for navigating the pan-European clinical assessment process for drugs and medical devices.
  • Joint Scientific Consultation Strategic guidance for engaging with HTA bodies under EU HTA Regulation, including strategic preparation for JSC submissions, stakeholder coordination, evidence generation advice, and post-JSC action planning.
  • HTA & Payer Early Dialogue Formal and informal payer insights for clinical trial designs including Joint Scientific Consultations, NICE scientific advice, Office of Market Access engagement, payer scientific advice, early access opportunities, advisory boards, and payer insights research.
  • Payer Value Communication Strategy Development of payer value communication materials including Global Value Dossiers, payer value driver identification, value message development, value story testing, objection handling, and formulary access tools.
  • Payer Insights Utilizes an extensive global payer network to obtain payer research insights addressing pharma pricing and market access strategy needs, including pharmaceutical pricing research, Target Product Profile testing, value message testing, payer advisory boards, and mock payer negotiations.
  • Pricing Strategy

Quantifiable outcome

  • 95% positive feedback from training course participants
  • +3 more outcomes

Companies that use Remap Consulting

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Remap Consulting technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Remap Consulting partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • MedvancecoreStrategic or Co-development PartnerAs the UK partner for Medvance, Remap Consulting addresses the market access challenges of pharmaceutical companies in Great Britain. Medvance is a European-wide healthcare consultancy group.
  • EUCOPEcoreStrategic or Co-development PartnerThe European Confederations of Pharmaceutical Entrepreneurs. Remap is an active member, presenter and regular contributor to EUCOPE, participating in industry discussions on pharmaceutical policy and market access.
  • RegulanetminorStrategic or Co-development PartnerRemap is a member of regulanet®, providing pricing and market access expert insights to support members of regulanet® network.
  • Swiss Biotech AssociationminorOthersAffiliation with the Swiss Biotech Association which represents the interests of the Swiss Biotech industry.
  • BHBIAminorOthersThe industry association for thought leadership, professional development and ethical standards for deriving insights within UK healthcare.
  • ISPORcoreOthersThe leading professional society for health economics and outcomes research (HEOR) globally. Remap participates in ISPOR events and conferences as presenters and attendees.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Remap Consulting competitors and assessment

Company assessment

Direct peers

  • Costello Medical: UK-based specialist pharma consultancy providing HTA submissions, market access, HEOR and value communications — directly comparable in service mix and target customer base to Remap.
  • Putnam Associates: Boutique pharma strategy and market access consultancy with strong HTA/payer expertise — comparable in offering, customer type (global pharma), and boutique positioning.
  • PRMA Consulting (now Avalere Health): Specialist pricing, market access and HEOR consultancy serving pharma and biotech — same core offering, same client set, and the firm where several Remap senior team members (e.g. Christina Baker, Nicole Lodowski) built their careers.
  • Mtech Access: UK-based specialist market access consultancy focused on pricing, HTA submissions and payer engagement for pharma/biotech — directly comparable niche positioning to Remap.
  • LCP Health Analytics: UK health economics and market access analytics consultancy — a specialist with comparable HTA/payer analytics focus (recent employer of Remap consultant Grace Miller).

Broad incumbents

  • Evidera (PPD / Pharmaceutical Product Development): Large HEOR, market access and HTA consulting arm within PPD, providing value evidence, pricing and payer communications — same service envelope as Remap but inside a much larger CRO platform.
  • IQVIA (formerly QuintilesIMS): Global life-sciences technology and consulting platform with market access and pricing practice — provides overlapping capabilities but as part of a much wider portfolio (Andrea Latour's previous employer).
  • Charles River Associates (Life Sciences practice): Global consulting firm with dedicated Life Sciences practice covering pricing, market access and commercial strategy for pharma — broader portfolio but directly comparable pricing/market access service line.
  • McCann Health (formerly McCann Complete Medical / FH): Global health communications and consulting group including FH/Real Chemistry providing market access, HEOR and value communications — overlaps with Remap's payer value communication work as part of a broader agency offering.

Regional players

  • Syreon Research Institute: European HEOR and market access research institute covering HTA submissions, health economics and pricing research — comparable service offering with primary European focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Remap Consulting social profiles

Digital presence

Remap Consulting compliance and trust

Trust signal

Compliance1 record

Remap Consulting financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Remap Consulting leadership team

Management profile

Number of profiles

Profiles10 records

Remap Consulting funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Remap Consulting M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Remap Consulting

What does Remap Consulting do?

Remap Consulting is a specialist market access and pharmaceutical pricing consultancy that helps drug developers launch products, optimize pricing, and navigate health technology assessment (HTA) and reimbursement processes across global markets. The firm delivers bespoke consulting across launch strategy, payer value communication, pricing strategy, business development commercial assessments, and market access training for pharmaceutical and biotechnology clients. Services are supported by a free AI-powered tool, the Remap JCA Advisor, for navigating EU HTA regulation.

Is Remap Consulting a public or private company?

Remap Consulting is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Remap Consulting founded?

Remap Consulting was founded in 2014. It employs 11 to 50 people.

Where is Remap Consulting based?

Remap Consulting is headquartered in Zug, Switzerland, in the Europe region.

How does Remap Consulting make money?

One revenue line is on record: consulting Services.

Who are Remap Consulting's main competitors?

Direct peers on record are Costello Medical, Putnam Associates, PRMA Consulting (now Avalere Health), Mtech Access and LCP Health Analytics. Broad incumbents are Evidera (PPD / Pharmaceutical Product Development), IQVIA (formerly QuintilesIMS), Charles River Associates (Life Sciences practice) and McCann Health (formerly McCann Complete Medical / FH). Syreon Research Institute is listed as a regional player.

Does Remap Consulting have an API?

No public API is recorded for Remap Consulting.

What industry is Remap Consulting in?

Remap Consulting's product category is Pharmaceutical Market Access Consulting. Its primary akta.pro industry code is BPAHACAG, Customer, Marketing & Sales Consulting, with a secondary code of BPAHACAB, Operations & Process Improvement Consulting. Its NAICS code is 54161 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales